Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulation following chemotherapy

M Obadina1, U Verma, M Hawkins

  • 1Vincent T. Lombardi Cancer Research Center, Georgetown University Hospital, Washington, DC, USA.

Breast Cancer Research and Treatment
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding pregnant women's health literacy strengths and challenges: a cluster-based exploration in the Health Literacy in Pregnancy (HeLP) study.

Public health·2025
Same author

High-speed computed tomography to visualise the 3D microstructural dynamics of oil uptake in deep-fried foods.

Nature communications·2025
Same author

Advances in diagnostic and therapeutic applications of mismatch repair loss in cancer.

DNA repair·2025
Same author

Employing innovation to enhance the safety and reliability of restorative surgical techniques for patients with familial adenomatous polyposis at a national referral centre.

Techniques in coloproctology·2024
Same author

Wheat gluten structure and (non-)covalent network formation during deep-fat frying.

Food research international (Ottawa, Ont.)·2024
Same author

Towards next generation digital twin in robotics: Trends, scopes, challenges, and future.

Heliyon·2023
Same journal

Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.

Breast cancer research and treatment·2026
Same journal

Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy.

Breast cancer research and treatment·2026
Same journal

Discrimination, spectrum, and clinical utility: ICG lymphography drainage time in axillary staging.

Breast cancer research and treatment·2026
Same journal

Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen.

Breast cancer research and treatment·2026
Same journal

Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.

Breast cancer research and treatment·2026
Same journal

Subjective socioeconomic status moderates the relationship between objective neighborhood disadvantage and quality of life in middle- and older-aged women with breast cancer.

Breast cancer research and treatment·2026
See all related articles

Immunomodulation therapy, using interferon and cyclosporine A, showed promise in a murine melanoma model. This approach may extend to breast cancer patients to enhance antitumor immune responses post-chemotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Therapy

Background:

  • Immunomodulation has emerged as a cancer treatment, mediating tumor regression in some patients.
  • This review examines immunomodulation strategies used in both transplant and non-transplant settings.
  • The study focuses on experiences with specific immunomodulatory agents and their outcomes.

Purpose of the Study:

  • To review the application of immunomodulation following chemotherapy in cancer treatment.
  • To evaluate the efficacy of combined interferon and cyclosporine A in a murine melanoma model.
  • To explore the potential of immunotherapy in breast cancer patients undergoing transplantation.

Main Methods:

  • Utilized interferon and cyclosporine A post-conventional chemotherapy in a murine B16 melanoma model (non-transplant setting).

Related Experiment Videos

  • Administered IL-2 activated peripheral blood stem cells (PBSC) immunotherapy in breast cancer patients (transplant setting).
  • Monitored outcomes including immune cell activity, graft-versus-host disease (GVHD), and time to reconstitution.

    • Main Results:

    • The combination of interferon and cyclosporine A generated MHC-unrestricted cytotoxic cells in the murine model.
    • In breast cancer patients, 20 out of 28 developed GVHD, with an average reconstitution time of 12 days.
    • These results suggest the feasibility and potential efficacy of immunomodulatory approaches.

    Conclusions:

    • Immunomodulation can induce an antitumor immune response.
    • The combination of interferon and cyclosporine A shows potential in preclinical models.
    • Further investigation into extending immunomodulation for breast cancer patients in a non-transplant setting is warranted.